Showing results (561-570 of 623) with videos related to

Sort By:
Pageof 63
The Oncologist|October 12, 2020
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient SettingSienna M Durbin, Leyre Zubiri, Andrzej Niemierko, et al.
International Journal of Radiation Oncology, Biology, Physics|March 28, 2025
Temporal Apparent Diffusion Coefficient Changes During Chemoradiation: An Imaging Biomarker for Tumor Response Monitoring and Spatial Recurrence Prediction in GlioblastomaDaniel Moore-Palhares, Liam S P Lawrence, Sten Myrehaug, et al.
The Oncologist|February 24, 2019
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic ControlChristopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey M Gill, et al.
The British Journal of Dermatology|October 12, 2018
Sunscreen applied at ≥ 2 mg cm-2 during a sunny holiday prevents erythema, a biomarker of ultraviolet radiation-induced DNA damage and suppression of acquired immunityJ Narbutt, P A Philipsen, G I Harrison, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory MelanomaDanny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
The Review of Scientific Instruments|October 2, 2007
Controller-area-network bus control and monitor system for a radio astronomy interferometerDavid P Woody, Bradley Wiitala, Stephen L Scott, et al.
Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal for Immunotherapy of Cancer|May 16, 2025
Tumor location as a risk factor for severe immune-related adverse eventsSteven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 28, 2023
Diffusion-weighted imaging on an MRI-linear accelerator to identify adversely prognostic tumour regions in glioblastoma during chemoradiationLiam S P Lawrence, Rachel W Chan, Hanbo Chen, et al.
Pageof 63